Modified Ligand-Gated Ion Channels for Selective Excitability Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing technologies struggle to control the levels of endogenous ligands such as acetylcholine (ACh) in ion channels, leading to uncontrolled ion transport and cellular excitability, which can result in unwanted activation and side effects on unintended targets.

Innovation Solution

Modified ligand-gated ion channels (LGICs) with specific amino acid substitutions in the ligand binding domain (LBD) and ion pore domain (IPD) are developed to enhance sensitivity to exogenous ligands and reduce sensitivity to endogenous ligands, allowing for selective control over ion transport and cellular excitability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If endogenous ligands such as acetylcholine are used to activate LGICs, then ion transport and cellular excitability are controlled, but the levels of endogenous ligands cannot be readily controlled leading to unwanted activation and side effects

Engineering Contradiction:

Improvecontrol of ion transportVSAvoidcontrol of ligand levels

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent introduces an engineered LGIC with modified ligand binding properties that acts as an intermediary system. The modified LGIC can be selectively activated by exogenous ligands while being resistant to endogenous ligands, providing controlled ion transport without direct dependence on uncontrollable endogenous ligand levels

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the ligand binding domain of the LGIC through amino acid substitutions, changing the binding parameters to prefer exogenous ligands over endogenous ligands. This parameter change enables selective activation and controlled ion transport independent of endogenous ligand concentration

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If modified LGICs with amino acid substitutions are used to enhance sensitivity to exogenous ligands, then selective control over ion transport is achieved, but cross-reactivity with endogenous channels may occur

Engineering Contradiction:

Improveselectivity of ligand bindingVSAvoidcross-reactivity with endogenous channels

Core Design Contradiction:

Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality changes by introducing specific amino acid substitutions at key positions in the ligand binding domain. These localized modifications alter the binding characteristics to prefer exogenous ligands while maintaining structural integrity and function of the channel

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the ligand binding function from the ion channel function by modifying only the ligand binding domain while preserving the ion pore domain. This segmentation allows independent optimization of ligand selectivity without affecting channel function

Inventive Principle:

Principle #1Segmentation

3Object-generated harmful factors

If modified LGICs are used to reduce sensitivity to endogenous ligands, then unwanted activation is prevented, but the ability to respond to physiological signals may be reduced

Engineering Contradiction:

Improveunwanted activationVSAvoidresponse to physiological signals

Core Design Contradiction:

Object-generated harmful factorsVSAdaptability or versatility

Solution Approach 1:

The modified LGIC serves as an intermediary that decouples physiological signal detection from ion channel activation. Exogenous ligands act as controlled mediators that can be administered at specific times and locations to activate the channel, providing precise temporal and spatial control

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent enables periodic or pulsatile activation of the LGIC through controlled administration of exogenous ligands. This periodic action allows activation only when needed, preventing continuous unwanted activation while maintaining the ability to respond to physiological demands

Inventive Principle:

Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified LGICs provide temporal and spatial control of ion transport and cellular excitability, minimizing side effects by enhancing the potency of exogenous ligands and reducing cross-reactivity with endogenous channels, thereby improving therapeutic efficacy and selectivity.

Implementation Method 1

Methodology Applied

Scientific EffectLigand binding: Absorption (physical)

Implementation Method 2

allowing for selective control over ion transport and cellular excitability

Methodology Applied

Scientific EffectIon transport: Diffusion

Data Source

PatentUS12570706B2Modified ligand-gated ion channels and methods of use

Publication Date: 2026.03.10 HOWARD HUGHES MEDICAL INST

AI summary

This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.